Floyd Petersen Sells 1,737 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd Petersen sold 1,737 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $25.69, for a total transaction of $44,623.53. Following the completion of the sale, the director owned 73,794 shares of the company’s stock, valued at approximately $1,895,767.86. This represents a 2.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock traded up $1.04 on Monday, reaching $26.31. The stock had a trading volume of 472,889 shares, compared to its average volume of 527,280. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $42.49. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 11.64, a P/E/G ratio of 7.08 and a beta of 0.91. The firm’s 50-day moving average is $25.52 and its two-hundred day moving average is $25.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.10. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%.The firm had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its position in shares of Amphastar Pharmaceuticals by 7.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,755,665 shares of the company’s stock worth $46,789,000 after purchasing an additional 128,781 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in shares of Amphastar Pharmaceuticals by 11.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock valued at $36,632,000 after buying an additional 130,672 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 14.5% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock worth $36,565,000 after acquiring an additional 160,034 shares during the period. Geode Capital Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock worth $22,348,000 after acquiring an additional 18,161 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in Amphastar Pharmaceuticals by 3.0% in the third quarter. Marshall Wace LLP now owns 874,068 shares of the company’s stock valued at $23,294,000 after acquiring an additional 25,383 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMPH. Barclays initiated coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price target for the company. Bank of America upped their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 8th. Finally, Needham & Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a report on Friday, November 7th. Two analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average target price of $31.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.